III
Information Services Group, Inc.
stock NASDAQ

Alpha Tau Medical (DRTS) is a $1.3B market cap company with multiple shots on goal to be a $10B - $50B company.
They have an alpha radiation platform that delivers high LET radiation directly into solid tumors (which make up 90% of all cancers.) The radiation is powerful but doesn’t spread which means that you get all the benefit of Cancer DNA strand demolition without risking surrounding tissue or compromising the immune system of the patient.
They have validated the platform with a PDMA certification in Japan and they are currently running five FDA approved trials across pancreatic, recurring GBM, skin, head & neck and prostate cancer. They’ve filed for a sixth trial to demonstrate their ability to hit a 100% DCR in combination with Keytruda.
The stock is at only $1.3B for two reasons: the institutional investors haven’t entered yet in real numbers. They recently got above $1B and there’s not a lot of daily volume.
The second reason is because the C suite, which holds a lot of equity, is brilliant. They are negotiating reimbursement in Japan right now and have enough to get FDA cert on skin but would prefer to kick off FDA with cert for recurring GBM. The FDA gave them ten rGBM cases to prove safety/feasibility and they crushed it: two CR (complete responses) in patients that have zero remaining options.
They signed a massive commercial agreement with Tolmar, a private company that dominates prostate cancer. DRTS will let Tolmar maker and sell for prostate (with an option on bladder) and DRTS keeps 60% of the net. They may replicate this model across other tumor types or in other geos and they’ll effectively become an IP and manufacturing shop.
Of the 10 rGBM patients, we know at least five have completed in the US and we are waiting for the MRI results. If they hit a CR on even one more of the patients, there is a high likelihood that DRTS moves into global first line treatment for rGBM because the only current standard of care is a pleasant social worker who explains that you need to make peace and say goodbye.
Like Moderna, Alpha Tau has early tested successfully with Merck’s $32B per year Keytruda. Keytruda, like all checkpoint inhibitors, comes with a massive weakness: checkpoint inhibitors only work on hot tumors, bolstering T cells in the area of the tumor. Alpha DaRTs turns cold tumors hot by blasting the bastards until their DNA strands are destroyed and their antigens leak out, signalling the T cells to come fight. That’s a massive game changer for the $50B per year checkpoint inhibitor market which has been searching for a way to overcome cold tumors.
Over the thousands of tumors they’ve treated, they’ve seen almost zero side effects and insurance companies love it because it’s a 45 minute long outpatient procedure.
The stock was just dual listed on the TASE which will expand volume, allow for some institutional buying and will put DRTS on at least two indexes where they will benefit from required buying.
Note: the platform is a medical device, not a drug. There is no Phase III trial. There is no placebo or BAT arm. There is no waiting for people to die. Alpha Tau is currently running tests in the US, Canada, Italy, Israel, Japan and other locations across Europe. The PMDA cert from Japan is so rigorous and well respected that it’s believed many Asia/Pac nations will accept it as a proxy.

I see a lot of new faces coming in since Moderna blew up and I thought I should share my Due Diligence checklists. I have one for Phase II and another for Phase III. I don't do Phase I because of reasons.

Don't get nervous. I plug a LOT of data and variables into a [Skills.md](http://Skills.md) file which I use across two separate AI models to both run reports and then confirm reports. It takes a while but the text output can and will seem like AI slop. The point is to have a checklist. I'm sharing mine.
Before I do, let me offer up some of what I've found to be best AI biotech best practices...

I limit my DD to a top 10 set of questions because there are way too many tickers out there.
1. Don't use Gemini. At least not yet. It will go off of outdated data from its training days and you'll be very sorry. Gemini will get better but it's not there right now.
2. Do use ChatGPT set on Sol High. I've found it to be the best at getting actual non-hallucinated answers. A lot of people prefer Claude and that's fine if you can afford Fable tokens. If not, you're likely better off with ChatGPT or even the latest Grok. You will need to pay for AI to get the real answers and research you seek. Sorry.
3. You need to learn how to set up skills within whichever AI bot you choose. You can turn the following 10 question due diligence Phase II checklist into a [skills.md](http://skills.md) file and call it with a ticker that you want to pursue.
4. You must always take whatever results you get from AI and run those results through another AI to confirm what you have is real. For instance, take the ChatGPT Sol high results and plug them into Claude Opus and ask the following question: "I think there may be at least one, if not two, mistakes in the following due diligence. FIND THEM and tell me whey they're incorrect." That will almost always uncover at least one or two mistakes which you will either take back to the original (or third) AI or you can always, you know, do real due diligence and find the actual answers.
5. Your due diligence and a checklist is table stakes to get into a ticker. It is NOT the same checklist you'll use to determine whether it's time to get OUT of a ticker. UNDERSTAND THIS. Entry and exit are two different things. Your thesis may break for reasons that you didn't foresee. One thing I've done - that I'm not sharing here yet - is my scanning [skills.md](http://skills.md) that goes through all of my holdings each day to determine whether anything fundamental has broken. Entry is easy'ish. Exit is hard. Always.

With that out of the way, you can copy/paste the following into your AI along with a ticker you're considering (make sure they're in or on the verge of Phase II trials) and see whether or not the following AI slop can make your ENTRY point a bit more informed. Good luck!
AI SLOP: GIVE ME THE PHASE II CHECKLIST...
Phase II is where the question changes from **“can the science translate?”** to **“is the human signal real, reproducible, and strong enough to justify a pivotal program?”**
At this stage, human data should dominate the diligence. Preclinical evidence still matters, but it should no longer be used to explain away weak clinical results.
Use three classifications:
**GATE** — failure can invalidate the investment thesis.
**MAJOR DISCOUNT** — does not necessarily kill the program, but materially reduces what you should pay.
**VALUATION INPUT** — affects probability-adjusted upside and downside.
* **1. Is the drug demonstrably biologically active in humans? — GATE** Look for a coherent translational chain:
**dose → exposure → target engagement → biological effect → clinical effect**
Evaluate human PK, pharmacodynamics, tissue penetration, target engagement, biomarkers, dose-response, and evidence that the proposed mechanism is actually occurring in patients.
The more directly the company can demonstrate mechanism in humans, the less you need to rely on animal biology.
**Red flag:** management responds to weak human efficacy by returning repeatedly to preclinical models or mechanistic theory.
* **2. How large and credible is the efficacy signal versus the correct comparator? — GATE** Effect size and comparator quality must be evaluated together.
For randomized trials, examine:
* treatment versus control performance
* absolute and relative effect size
* confidence intervals
* response durability
* subgroup consistency
* missing data and censoring
* investigator versus central review
For single-arm studies, historical controls must match the treated population in:
* disease severity
* prior lines of therapy
* refractory status
* biomarker status
* age and performance status
* geography
* assessment methodology
* scan or evaluation schedule
* supportive care
* calendar period and evolving standard of care
A 40% response rate is meaningless until you know whether comparable patients normally achieve 5%, 20%, or 35%.
**Red flags:** the company emphasizes responder subsets while avoiding all-comers data; repeatedly changes the historical comparator; or compares against a population materially easier to treat than the study population.
* **3. Is the endpoint clinically meaningful and suitable for a pivotal program? — GATE** Determine whether the Phase II endpoint:
* measures something patients or regulators care about
* is validated or well accepted
* is objective where possible
* can be reproduced in Phase III
* has a credible relationship to eventual clinical benefit
* has been discussed with regulators
Distinguish a true surrogate endpoint from a biomarker that merely changes.
Review [ClinicalTrials.gov](http://ClinicalTrials.gov) history for endpoint changes after enrollment began.
**Red flag:** the primary endpoint changes after meaningful enrollment without a convincing scientific or regulatory explanation, especially if the new endpoint favors the emerging data.
* **4. Is the selected dose actually the right dose? — GATE** Phase III dose selection should be evidence-based, not inherited from the highest tolerated dose.
Evaluate:
* exposure-response
* dose-response
* target saturation
* efficacy by dose
* toxicity by dose
* dose reductions
* interruptions
* discontinuations
* duration of exposure
* interpatient PK variability
Ask whether a lower dose preserves efficacy with better tolerability, or whether higher exposure produces additional benefit.
**Red flag:** the company enters pivotal development while still uncertain which dose provides the optimal benefit-risk profile.
* **5. Is the safety profile acceptable at the exposure required for efficacy? — GATE / MAJOR DISCOUNT** Focus on whether patients can remain on treatment long enough to benefit.
Examine:
* treatment-related serious adverse events
* deaths
* discontinuations
* dose reductions
* interruptions
* cumulative toxicity
* organ-specific toxicity
* class-specific risks
* monitoring burden
* interactions with standard-of-care therapy
Safety must be judged relative to disease severity and available alternatives.
**Red flag:** efficacy depends on exposure that produces frequent dose reductions, discontinuations, or cumulative toxicity.
* **6. How much Phase II effect degradation can the pivotal program tolerate? — GATE** Assume the Phase II point estimate is too optimistic.
Model what happens if efficacy deteriorates by:
* 10%
* 20%
* 30%
* 40%
Stress-test:
* smaller true treatment effect
* worse control-arm performance
* broader Phase III population
* additional geographies
* less experienced sites
* more heterogeneous patients
* lower adherence
* more missing data
The strongest Phase II programs do not require Phase III to reproduce an unusually favorable early result exactly.
**Red flag:** a modest reduction in effect size makes the proposed pivotal study statistically unlikely to succeed.
* **7. Can the Phase II product be bridged cleanly into Phase III and commercial manufacturing? — GATE / MAJOR DISCOUNT** Determine whether the product used in Phase II is materially representative of what will be used in Phase III and ultimately sold commercially.
Ask about changes in:
* manufacturing site
* scale
* formulation
* device or delivery system
* raw materials
* cell line
* purification
* analytical methods
* release specifications
* storage
* stability
* container closure
For biologics, cell therapies, gene therapies, and complex products, assess the comparability package carefully.
For small molecules, determine whether formulation changes alter exposure.
**Red flag:** Phase III will use materially different product and a substantial comparability or bridging package remains unresolved.
* **8. Has FDA agreed with the pivotal-development strategy? — GATE** Determine what regulators have actually agreed to regarding:
* indication
* patient population
* dose
* endpoint
* control group
* statistical analysis
* trial size
* duration
* safety database
* accelerated versus traditional approval
* confirmatory requirements
* manufacturing expectations
Distinguish:
**“FDA provided feedback”**
from:
**“FDA agreed that this program could support registration if successful.”**
Review actual regulatory disclosures rather than relying solely on management characterization.
**Red flag:** the company is preparing an expensive pivotal program while major questions about endpoint, population, dose, or registration strategy remain unsettled.
* **9. Can the company enter Phase III from a position of financial strength? — MAJOR DISCOUNT** The key Phase II financing question is not simply whether cash lasts until Phase III.
Ask:
**Can management start or negotiate Phase III on its own terms, or must it raise or partner from weakness?**
Evaluate:
* current cash
* quarterly burn
* cost to complete Phase II
* cost to prepare Phase III
* manufacturing commitments
* debt
* milestones
* warrants
* converts
* ATM capacity
* fully diluted shares
Then assess strategic leverage:
* Can the company fund initial Phase III work independently?
* Is the Phase II package strong enough to attract competitive partnering interest?
* Must the company accept whatever terms are available?
* Is a highly dilutive raise unavoidable immediately after data?
**Red flag:** the company must finance or partner regardless of the quality of the Phase II result and has insufficient cash to create negotiating leverage.
* **10. Does today's valuation compensate you for the probability of pivotal success? — VALUATION INPUT** Build a probability-adjusted value rather than simply assigning a successful drug a peak-sales multiple.
Model:
* probability Phase II signal is real
* probability Phase III succeeds
* probability of approval
* dilution before approval
* partnership economics
* royalties
* milestones
* remaining patent life
* regulatory exclusivity
* addressable population
* pricing
* reimbursement
* competition
* manufacturing cost
* likely strategic value
At minimum model:
**Strong Phase III success**
**Marginal or mixed Phase III result**
**Pivotal failure**
The investment question is not:
**“Is the Phase II data exciting?”**
It is:
**“After allowing for regression to the mean, regulatory risk, manufacturing risk, financing, and dilution, does today's enterprise value still leave asymmetric upside?”**
# Phase II decision rule
Before investing, you should be able to say:
**“The drug is demonstrably active in humans, the efficacy signal is large relative to the correct comparator, the dose and endpoint are defensible, the result can deteriorate meaningfully and still support Phase III success, the commercial product can be manufactured comparably, regulators support the pivotal path, and the company has enough leverage to finance or partner the next stage without destroying shareholder value.”**
If several of those statements require optimistic assumptions, the Phase II program is not yet de-risked enough to deserve a Phase III-style valuation.

Keytruda is only meant to be used up to Stage 3, according to their own documentation:

a kind of skin cancer called [melanoma](https://www.keytruda.com/#expand-melanoma).
* Each may be used when your melanoma has spread or cannot be removed by surgery (advanced melanoma).
* It is not known if KEYTRUDA and KEYTRUDA QLEX are safe and effective in children with advanced melanoma.
* Each may be used in adults and children 12 years of age and older with stage IIB, stage IIC, or stage III melanoma, to help prevent melanoma from coming back after it and lymph nodes that contain cancer have been removed by surgery.

From the announcement:
RAHWAY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Moderna, Inc. (NASDAQ: MRNA) today announced positive topline results from the Phase 3 INTerpath-001 trial evaluating adjuvant treatment with intismeran autogene (intismeran; V940 or mRNA-4157), a novel investigational mRNA-based individualized neoantigen therapy (INT) being jointly developed by Merck and Moderna, in combination with KEYTRUDA^(®) (pembrolizumab), Merck’s anti-PD-1 therapy, in patients with completely resected stage IIB-IV melanoma. The trial met its primary endpoint of recurrence-free survival (RFS) and a key secondary endpoint of distant metastasis-free survival (DMFS). This represents the first positive Phase 3 readout for an individualized neoantigen therapy (INT) and for an mRNA-based cancer therapy, as well as the first Phase 3 study to demonstrate a clinically meaningful improvement over KEYTRUDA alone, a standard-of-care immunotherapy, in the adjuvant setting for patients with resected melanoma.

So, the announcement states clearly that the combination was studied up to and through stage 4, whereas Keytruda by itself is only indicated up to stage 3. I'm sure dermatologists prescribe it for stage 4 anyway, as I'm sure the risk/reward is positive regardless.
IF the data, which they say they are presenting soon, shows it does stop metastasis elsewhere to a statistically significant degree, which they call DMFS for distant metastasis free survival, that's the big deal, as far as my wife is concerned, for this combination.
I understand your bear case, but it's based on the data not being released yet, and this being merely an announcement. That's the risk. The reward is if the data really does show what they claim. We'll see.
The market reaction is not as overblown as it appears, because they are ALSO studying this for other cancers that Keytruda is used for. So the market is pricing in increased odds for success not just with this cancer, but with the other cancers being studied, and of course if it works for these then mRNA individualized vaccines can work for others beyond those currently being studied. Admittedly it's an optimistic take by the market so far, but not wildly so given the potential.

isn't that what basically triggered the Boston Tea Party when King George III restricted colonist trade?

In this thread SLS is closing in on the end of phase III. CING and UNCY both recently had Complete Response Letters (CRLs) on manufacturing issues and are pending new PDUFA dates.
CRLs are a red flag and tank a stock, but if the reason for CRL isn't related to the drug itself, it can be a buying opportunity. Pay attention to the cash runway, if they need to dilute significantly to get to a new PDUFA date, it's risky. If they can get to a likely PDUFA date, they may still need to dilute to reach commercialization, but that likely isn't as dilutive if they can wait a bit as there does tend to be a run up on the way to a new PDUFA date. Just be aware that CRL can be evidence of poor leadership, if there is something they missed. And companies can and do go through multiple CRL cycles sometimes.

Look up Basel III and the great taking doco. If you don’t hold it you don’t own it.

Don't forget to go camping once in a while y'all. Unplugging and looking at trees and creeks and stuff is good for the soul!
PROOF - https://imgur.com/3ERxFKo
Offers accepted on multiple items.
WATCH OUT FOR IMPERSONATORS. I WILL NEVER OPEN A CHAT WITH YOU. WANT IT? CHAT ME UP AFTER YOU COMMENT.
BIN it and Win it. First to BIN gets it. Otherwise I decide the order in which I respond to chats. And to be fair to others BIN means Buy It **Now**, so no dilly-dallying or haggling.
TABLE OF CONTENTS
* New Items
* Now on Sale
* Vintage Silver
* Gold
* Lunargrams
* Premium Silver
* Slabbed Silver
* Mini-Fig Weapons
* Silver Casters
* Copper Casters
/---------------------------
##NEW ITEMS
**~~3x~~ 2x - 1945 Dos Y Medios Gold. BU.**
* $293 each
* https://imgur.com/buJWxuz
**1x - 1925-S California Half Dollar with Prospector obverse and Bear reverse. Incredible golden toning. The coin dealer who sold it to me thinks it's AU58. I am inclined to agree. At minimum I would say it's a problem free coin and I would be happy to provide more pictures. Comes in capsule.**
* $225
* https://imgur.com/uP7dQ1V
* https://imgur.com/5lVfeoF
**1x - 2014 PAMP 100g Silver Lunar Calendar Horse in assay. Peely is starting to unpeel, but assay and bar are perfect. Some toning on top reverse of bar.**
* $349
* https://imgur.com/EPJVerU
* https://imgur.com/SqjQUvj
**1x - 2013 PAMP 100g Silver Lunar Calendar Snake in assay. Clean and sweet.**
* $349
* https://imgur.com/ikB2Ott
* https://imgur.com/fRuGIwZ
**50x - Aztec 1/10 oz Silver Rounds**
* $$10 each
* https://imgur.com/yiLpqU3
* https://imgur.com/az6JSaH
/---------------------------
##NOW ON SALE
**~~5x~~ 4x - 10g Antiqued Zomboobies Silver Hand Cast**
* ~~$55 each~~ $49 each
* https://imgur.com/0qwPPwT
* https://imgur.com/tqcwyCu
**~~5x~~ ~~4x~~ 3x - 2022 Germainia 1oz Silver Allegories 5 Mark. Version 1.**
* ~~$89 each~~ $83 each
* https://imgur.com/4L34Bzr
**~~5x~~ ~~4x~~ 3x - 2022 Germainia 1oz Silver Allegories 5 Mark. Version 2.**
* ~~$89 each~~ $83 each
* https://imgur.com/iDPpEWC
**4x - 2014 Kook with Horse Privy**
* ~~$89 each~~ $83 each
* https://imgur.com/CBbUV9I
* https://imgur.com/GQLZYST
**1x - 2015 Kook with Ram Privy**
* ~~$89 each~~ $83 each
* https://imgur.com/nwabb05
* https://imgur.com/aif2TwR
/---------------------------
##VINTAGE SILVER
**1x - 5oz CCM California Crown Mint Trade Unit Bar. Toner in capsule.**
* $425
* https://imgur.com/8ha16O1
* https://imgur.com/9WR3qzn
**1x - A-Mark 10oz Chonker Ingot. The original stacker! Lot #787**
* $750
* https://imgur.com/tFCsKSU
* https://imgur.com/7e1MVOk
**4x - 1981 A-Mark Chunkies. Everyone's favorite ingot!**
* $89 each
* https://imgur.com/umXfDvy
* https://imgur.com/f8DpQ6X
**2x - 1oz Silver Williams Manufacturers Refiners Bars. THis is one proof-like bar! One has toning, but hard to see in pics.**
* $99 each
* https://imgur.com/X0wwE8e
* https://imgur.com/4iH8OG9
**2x - 1oz Oxford Bars with blank back.**
* $85 each
* https://imgur.com/SMCVWSV
* https://imgur.com/utIkA7N
/---------------------------
##GOLD
**1x - 2019 1/20 Perth Lunar Series 2 Pic in original capsule**
* $299
* https://imgur.com/KTqsViz
* https://imgur.com/xzrWdMu
**1x - 2016 1/20 Perth Lunar Series 2 Monkey in original capsule**
* $299
* https://imgur.com/advzpp7
* https://imgur.com/d41IYPP
**1x - 2011 1/20 Perth Lunar Series 2 Rabbit in original capsule**
* $299
* https://imgur.com/u5bVpvB
* https://imgur.com/11j3wgY
**1x - 2002 1/20 Perth Lunar Series I Horse in original capsule**
* $299
* https://imgur.com/0VmySYm
* https://imgur.com/pHMwN6p
**1x - 2001 1/20 Perth Lunar Series I Snake in original capsule**
* ~~$310~~ $299
* https://imgur.com/zPD7IXm
* https://imgur.com/bNVcdgX
/---------------------------
##LUNARGRAMS
We have a great new maker out there in Cali making these sweet little 1/10 silver round hand stamped lunargrams. Comes with stickers and capsules.
**1/10oz Silver Hand Stamped Lunargram Prototypes.**
* https://imgur.com/iU6vKWO
* $12 each
* 16x - Horses
* 2x - Monkey
* 1x - Dog
* 3x - Goat
* 1x - Rabbit
* 1x - Ox
* 1x - Snake
* 1x - Pig
/---------------------------
##PREMIUM SILVER
**~~5x~~ ~~3x~~ 1x - 2012 Perth 1oz Red Colorized Dragon Proof in OGP with COA**
* $109 each
* https://imgur.com/WCLu9kp
* https://imgur.com/j1sRIGU
* https://imgur.com/NxuyNcw
**4x - 2002 1oz Perth Lunar Series I Horse in capsule**
* $105 each
* https://imgur.com/h57rSNN
* https://imgur.com/kQHGAvV
**~~2x~~ 1x - 2003 1oz Perth Lunar Series I Goat in capsule**
* $105 each
* https://imgur.com/7oy6pUf
* https://imgur.com/vz3fJv4
**3x - 1/2oz 2015 Perth 1/2oz Lunar Year of the goat. Fresh from a sealed roll and in original capsule.**
* $45 each
* https://imgur.com/ulKNAb2
* https://imgur.com/P0S4sQX
**1x - 2014 10oz Kookaburra in capsule. Coin is pristine but the cap has signs of handling.**
* $799
* https://imgur.com/4wejW6P
* https://imgur.com/xedoY1u
**1x - 2016 10oz Kookaburra in capsule. Coin is pristine but the cap has signs of handling.**
* $799
* https://imgur.com/Vl1cwrv
* https://imgur.com/Q3zujJE
/---------------------------
##SLABBED SILVER
**1x - 2019 Perth Kookaburra NGC MS69 Early Issue**
* $85
* https://imgur.com/Dds2FUD
* https://imgur.com/W2OGeyq
**1x - 2025 1oz Perth Lunar Series III Snake NGC MS70, red core**
* $99
* https://imgur.com/RzjYes9
* https://imgur.com/aMzBIf1
**1x - 2025 1/2oz Perth Lunar Series III Snake NGC MS70, black core**
* $59
* https://imgur.com/o7z1JHF
* https://imgur.com/mbBeGhQ
/---------------------------
##HAND CAST LEGO MINI-FIG WEAPONS
* ALBUM - https://imgur.com/a/Z7K4Vjc
* $8 per gram (1-2 grams pieces)
* $7 per gram (3+ gram pieces)
* Order by number in this pic, which also shows weights: https://imgur.com/U3VJGDN
* SOLD - 1-13, 15-19, 20, 22, 25-27
* AVAILABLE - 14, 21, 23, 24, 28
/---------------------------
##SILVER HAND POURED CASTERS
**Silver Cast Weapons**
* https://imgur.com/AhgkY3w
* Sai 1 - 9g - $59
* Sai 2 - 9g - $59
* Gun 1 - 5g - $35
* ~~Gun 2 - 10g - $69~~ SOLD
* ~~Gun 3 - 12g - $72~~ SOLD
* Gun 4 - 3g - $21
**1x - 14g Angel Wings Hand Cast**
* $65
* https://imgur.com/SJYG4x0
* https://imgur.com/oid20iI
**1x - 1.11oz Gas Mask Face. Limited Mintage #3/21**
* $139
* https://imgur.com/l4enzSo
* https://imgur.com/pA7k2Z5
**2x - 9g Donuts with sprinkles hand pour.**
* $48 each
* https://imgur.com/5rONBoZ
* https://imgur.com/Oa3ZCAq
* https://imgur.com/DPtt3VG
/---------------------------
**COPPER HAND POURED CASTERS
**2x - 2.5+ oz Dragon Rolos**
* $5 each
* https://imgur.com/xbow8nn
* https://imgur.com/cK0eOH2
/---------------------------
ALL ITEMS SIGMA VERIFIED
USA PAYMENT - Zelle, Venmo (NO NOTES), Paypal F&F, fiat cash, checks, money orders. Checks and Money orders need to fully clear first before I ship anything.
USA SHIPPING - $6-19. I pack and ship like I like to receive it. Nicely secured, padded, and no jingling. I hand deliver to post office for scanning and will provide tracking. On higher dollar sales I may require registered mail charged at cost.
RESPONSIBILITY - My responsibility ends when the package shows delivered in tracking. If you have a problem with porch pirates I recommend signature confirmation, which I can provide at cost. All items sigma verified. I stand behind what I sell 100%.
ORDERS OVER $1000 REQUIRE PRIORITY w/ SIGNATURE TO BE FULLY INSURED. IF YOU WANT TO SAVE $4, REFUSE SIGNATURE AND TAKE RESPONSIBILITY FOR PACKAGE. (TOTAL COST IS $14-19 depending on size)
SECURITY - All my proof pictures will contain my ZENPATHFINDER silver round name badge that u/UnresolvedEgo made. I love it. You should consider a name badge of your own if you sell. I am no dummy and any "mod" that says I am banned and they need my password to see my chats gets a nice teabagging pic and is reported. I will always use my custom name tag to provide proof via chat, just ask. I have 2FA on my account. LETS KEEP THIS SUB SAFE!